The biopharmaceutical company HIPRA, a member of CATALONIA.HEALTH, launches HIPRA Biotech Services, its new unit aimed at offering development and manufacturing services of biological products to companies in the biotechnology and pharmaceutical sectors. HIPRA Biotech Services covers the entire life cycle of the product, from the initial phases of research and development to production on a commercial scale. This comprehensive proposal includes multiple technologies and biological modalities, offering its customers flexibility, personalized solutions and the highest quality, complying with the requirements of international regulatory agencies.
The new unit will put on the market more than 7,000 litres of bioreactor capacity for mammalian cell culture and more than 8,000 litres of fermentation capacity for microbial crops. It also has an aseptic filling line for roads with insulation technology. These figures position HIPRA Biotech Services as one of the main CDMOs in Europe in the manufacture of biological products.
In addition, it has a multidisciplinary team made up of 1,400 highly specialized professionals, including scientists, engineers, operators and analysts, among others. This team works closely with customers to provide solutions adapted to their needs, complying with the strictest requirements of the market and guaranteeing quality in all phases of the process. Moreover, the new unit will be led by Eduard Viladesau, General Director of HIPRA Biotech Services.
“With HIPRA Biotech Services we put at the service of other companies the knowledge and experience accumulated over more than 50 years in biotechnology, together with our technical and scientific capabilities and our commitment to excellence. For decades, we have been a strategic reference in animal health, consolidating innovative and high-quality solutions. In recent years, we have successfully expanded our experience towards human health, which allows us to offer comprehensive knowledge in the development and manufacture of biologicals. This CDMO model reflects our mission to provide innovative and sustainable solutions that contribute to improving global health,” says Carles Fàbrega, Director General of HIPRA Human Health.
Related news:
Comments